Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel

Journal of the American Academy of Dermatology

Volumn 58, Issue 1, 2008, Pages 25-32

  Halevy, Sima ^a   Ghislain, Pierre Dominique ^b   Mockenhaupt, Maja ^c   Fagot, Jean Paul ^d   Bouwes Bavinck, Jan Nico ^e   Sidoroff, Alexis ^f   Naldi, Luigi ^g   Dunant, Ariane ^b,h   Viboud, Cecile ^d   Roujeau, Jean Claude ^b  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b HENRI MONDOR HOSPITAL   (France)

^c UNIVERSITY OF FREIBURG   (Germany)

^d INSERM   (France)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^g OSPEDALI RIUNITI   (Italy)

^h INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; AMINOPENICILLIN; CARBAMAZEPINE; COTRIMOXAZOLE; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; LAMOTRIGINE; NEVIRAPINE; PHENOBARBITAL; PHENYTOIN; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG USE; EUROPE; FEMALE; HUMAN; INCIDENCE; ISRAEL; MAJOR CLINICAL STUDY; MALE; POLYPHARMACY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

ADULT; AGED; ALLOPURINOL; CASE-CONTROL STUDIES; DEMOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EPIDERMAL NECROLYSIS, TOXIC; EUROPE; FEMALE; GOUT SUPPRESSANTS; HUMANS; INCIDENCE; ISRAEL; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; STEVENS-JOHNSON SYNDROME;

EID: 37349064108     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2007.08.036     Document Type: Article

References (29)

1. Sweetman S, editor. Martindale: the complete drug reference [database online]. London: Pharmaceutical Press; 2006. Electronic version; Greenwood Village, Colo: Thomson Micromedex. Edition expires September 2006.
2. Aubock J., and Fritsch P. Asymptomatic hyperuricemia and allopurinol induced toxic epidermal necrolysis. Br Med J 290 (1985) 1969-1970
3. Arellano F., and Sacristan J.A. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother 27 (1993) 337-343
4. Auquier-Dunant A., Mockenhaupt M., Naldi L., Correia O., Schroder W., Roujeau J.C., et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 138 (2002) 1019-1024
5. Bastuji-Garin S., Rzany B., Stern R.S., Shear N.H., Naldi L., and Roujeau J.C. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 129 (1993) 92-96
6. Rzany B., Mockenhaupt M., Baur S., Schroder W., Stocker U., Mueller J., et al. Epidemiology of erythema exudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry. J Clin Epidemiol 49 (1996) 769-773
7. Roujeau J.C., Kelly J.P., Naldi L., Rzany B., Stern R.S., Anderson T., et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 333 (1995) 1600-1607
8. Struthers A.D., Donnan P.T., Lindsay P., McNaughton D., Broomhall J., and MacDonald T.M. Effect of allopurinol on mortality and hospitalizations in chronic heart failure: a retrospective cohort study. Heart 87 (2002) 229-234
9. Mockenhaupt M., Viboud C., Dunant A., Naldi L., Halevy S., Bouwes Bavinck J., et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs, the EuroSCAR study. J Invest Dermatol (2007). doi:10.1038/sj.jid.5701033 Published online September 6, 2007
10. Kelly J.P., Auquier A., Rzany B., Naldi L., Bastuji-Garin S., Correia O., et al. An international collaborative case-control study of severe cutaneous adverse reactions (SCAR): design and methods. J Clin Epidemiol 48 (1995) 1099-1108
11. Lin M.S., Dai Y.S., Pwu R.F., Chen Y.H., and Chang N.C. Risk estimates for drugs suspected of being associated with Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control study. Intern Med J 35 (2005) 188-190
12. Klasco RK. Drugdex system [database online]. Greenwood Village, Colo: Thomson Micormedex. Edition expires September 2006.
13. Devlin J.W., Bellamy N., and Bayliff C.D. Observations and effects of educational consults on allopurinol prescribing. Can J Hosp Pharm 45 (1992) 21-27
14. Smith P., Karlson N., and Nair B.R. Quality use of allopurinol in the elderly. J Qual Clin Pract 20 (2000) 42-43
15. Stamp L., Gow P., Sharples K., and Raill B. The optimal use of allopurinol: an audit of allopurinol use in South Auckland. Aust N Z J Med 30 (2000) 567-572
16. McClintock A.D., Egan A.J., Woods D.J., and Pillans P.I. A survey of allopurinol dosage prescribing. N Z Med J 108 (1995) 346-347
17. McInnes G.T., Lawson D.H., and Jick H. Acute adverse reactions attributed to allopurinol in hospitalized patients. Ann Rheum Dis 40 (1981) 245-249
18. Fam A.G., Dunne S.M., Iazzetta J., and Paton T.W. Efficacy and safety of desensitization to allopurinol following cutaneous reactions. Arthritis Rheum 44 (2001) 231-238
19. Gurwitz J.H., Kalish S.C., Bohn R.L., Glynn R.J., Monane M., Mogun H., et al. Thiazide diuretics and the initiation of anti-gout therapy. J Clin Epidemiol 50 (1997) 953-959
20. Yamamoto T., Moriwaki Y., Takahashi S., Tsutsumi Z., and Hada T. Effect of furosemide on renal excretion of oxypurinol and purine bases. Metabolism 50 (2001) 241-245
21. Dincer H.E., Dincer A.P., and Levinson D.J. Asymptomatic hyperuricemia: to treat or not to treat. Cleve Clin J Med 69 (2002) 594 597, 600-2
22. Singer J.Z., and Wallace S.L. The allopurinol hypersensitivity syndrome: unnecessary morbidity and mortality. Arthritis Rheum 29 (1986) 82-87
23. Bellamy N., Brooks P.M., Emmerson B.T., Gilbert J.R., Campbell J., and McCredie M. A survey of current prescribing practices of anti-inflammatory and urate-lowering drugs in gouty arthritis in New South Wales and Queensland. Med J Aust 151 (1989) 531-532 535-7
24. Zell S.C., and Carmichael J.M. Evaluation of allopurinol use in patients with gout. Am J Hosp Pharm 46 (1989) 1813-1816
25. Stuart R.A., Gow P.J., Bellamy N., Campbell J., and Grigor R. A survey of current prescribing practices of antiinflammatory and urate-lowering drugs in gouty arthritis. N Z Med J 104 (1991) 115-117
26. Khoo B.P., and Leow Y.H. A review of inpatients with adverse drug reactions to allopurinol. Singapore Med J 41 (2000) 156-160
27. Harris C.M., Lloyd D.C., and Lewis J. The prevalence and prophylaxis of gout in England. J Clin Epidemiol 48 (1995) 1153-1158
28. Gresser U., Gathof B., and Zollner N. Uric acid levels in southern Germany in 1989: a comparison with studies from 1962, 1971, and 1984. Klin Wochenschr 68 (1990) 1222-1228
29. Agence Française de Securité Sanitaire des Produits de Santé. Analyse des ventes de médicaments aux officines et aux hôpitaux en France: 1991-2001. AFSSAPS ed, Paris 2003. Available at: http://www.agmed.sante.gouv.fr. Accessed September 18, 2007.